Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

At the recent 10th Clinical Trials on Alzheimer’s Disease meeting in Boston it was announced that “Cognition Therapeutics’ leading drug candidate for mild-to-moderate Alzheimer’s disease, CT1812, was shown to be well-tolerated and to lower brain levels of proteins involved in the disease.”